However, among those patients with CKD only 12.1% had their CKD documented as either a diagnosis code or description in the fifteen month chart review. Clinicians were more successful in recognizing CKD in more advanced stages (e.g., 3 and 4), but still missed ne...
Since inflammation and oxidative stress are evident in moderate stages of CKD, the key hypothesis is that controlling toxin levels can reduce CKD complications and slow CKD progression. Enzobiotics can modulate the intestinal microbiota and improve the absorption of proteins in the small intestine to ...